Global pharmaceutical & biotechnology outlook 2013 mature biotech - Reports Corner

  • 149 views
Uploaded on

Profitable Biotech (Mature Biotech) and non-Profitable Biotech companies (Rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the …

Profitable Biotech (Mature Biotech) and non-Profitable Biotech companies (Rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma.

https://www.reportscorner.com/reports/10017/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Mature-Biotech/

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
149
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
9
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. RCReports CornerGlobal Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech
  • 2. DescriptionDescriptionReports Cornerwww.reportscorner.comProfitable Biotech (Mature Biotech) and non-Profitable Biotechcompanies (Rising stars) have developed innovative drugs fortreatment of chronic and non chronic diseases. In the next fiveyears the distinction between mature biotech companies andlarge global pharma is likely to disappear as investment in R&Dand acquisition start delivering and Market Cap match the largeglobal pharma.
  • 3. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comProfitable Biotech (Mature Biotech) and non-Profitable Biotechcompanies (Rising stars) have developed innovative drugs fortreatment of chronic and non chronic diseases. In the next fiveyears the distinction between mature biotech companies andlarge global pharma is likely to disappear as investment in R&Dand acquisition start delivering and Market Cap match the largeglobal pharma. Dividend and consolidation could be the futuredrivers and continue to attract long term investors. Optimismprevails around the future of this sector as a whole which wasreflected in the unprecedented rally in shares in 2012. We expectthis trend to continue in the next five year driven by launch ofInnovative drugs catering to unmet needs in Alzheimers, HCV,osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis,Cancer and orphan diseases. Drug approvals and label expansionof existing portfolio of launched drugs and data from late stagepipeline drugs should maintain the growth momentum andinvestors interest.
  • 4. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com2012 was recovering from the big acquisitions made in the lastfive years by this sector but we expect exercising of some restrainfor similar large acquisitions as investors would like to see thereturns reflected in the top-line and EPS. However in- licensing ofearly or mid stage compounds or small acquisitions will continuesince the Rising Stars will keep throwing the bait by taking risksand innovate using novel technology platforms or validating noveltargets for treating diseases.Patent expiry impact is modest for the next five years for thesector as majority have "not so easy to copy" biologics and otherdrugs in their portfolio. They however are not complacent and arenot leaving any stones unturned to meet the challenges as well asexploring emerging market opportunities with local partners.Favorable regulatory environment should finally see biosimilarmAbs entry in regulated markets in the next five years. Theoptimism of biosimilar players is reflected in the maturingpipeline.
  • 5. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comPara IV Filing from other generic players continues to pour leavingroom for surprises and volatility.Global Biopharmaceutical Outlook 2013 of the Mature Biotechsector released by MP Advisors provides valuations and an indepth analyses of biotech companies, their launched drugportfolio and promising drug candidates in the pipeline. Thereport discusses the competitive landscape of the targetedtherapy areas and the innovative strategy each company isdeploying to create or retain its leadership in the therapy areas.Forecast for major marketed drugs and drugs in the pipeline areincluded after factoring, competition, and risks from changingregulatory environment which could change the future marketdynamics. Risk reward analyses of important upcomingmilestones of the companies are included which should help fundmanagers as well as pharma company management to makecritical decisions.
  • 6. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe detailed 110 pages report contains:Macro AnalysisPerformance of the Mature Biotech companies recommended byMP Advisors in 2012 -report card is very impressive and weexpect the positive sentiments to prevail in 2013 and beyondValuation Multiples and Fundamentals- Drivers of Growth.MP Advisors Proprietary Sum-of-The-Parts Valuation and TopPicks for 2013Drug Approvals 2012-15Key Milestones During 2013/14Impact on revenue 2012-2017 from Patent Expiry and Strategiesdeployed to meet the challenges.Pipeline of Biosimilar mAbsJoint Ventures between innovators and biosimilar playersMerger & Acquisitions Forecast- 2013-2020In-depth Company Analysis and Reports on
  • 7. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comAcorda - AMPYRA addresses co-morbidities associated withmultiple sclerosis (MS) and with no competition, future growth inUS and EU to sustain the current valuation. Pipeline remains afree call option.Alexion - Innovative drugs, diversification and focus on orphandiseases will continue to lend stability. Availability of Soliris(eculizumab, C5a inhibitor) indicated for Paroxysmal nocturnalhemoglobinuria (PNH) and Hemolytic-uremic syndrome (HUS) inother geographies along with label expansion should drive growthin the next five years. Pipeline (Asforase alfa, ALXN1102/1103,ALXN1007) beyond soliris is also maturing.Amgen - Sales of denosumab (Prolia: PostmenopausalOsteoporosis, male osteoporosis and XGEVA: skeletal-relatedevents in patients with bone metastases from solid tumors) andnovel compounds in the pipeline targeting bone health, cancerand Hypercholesterolemia should sustain Amgens reputation asan innovator.
  • 8. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThrough acquisitions and collaboration, Amgen is poised to tapthe emerging market opportunities.Biogen Idec - Poised to sustain its leadership in MS with the wellawaited launch of the best in class oral therapy BG-12 (dimethlyfumerate, R). Diversification in other therapy area - hemophilia isthe future driver.Celgene – Leadership in hematological cancers will be sustainedwith the launch of pomalidomide. Diversification in autoimmuneand inflammatory diseases and label expansion of marketeddrugs will drive growth. Risk of Para IV challenges remain.Gilead - Leading in HIV and poised for a similar feat in HCV.Product pipeline beyond the Anti-viral is maturing and promising.Grifols – Stable growth in the plasma protein business, while IVIGopportunity in Alzheimers disease remains a wild card.Onyx - Oncology drugs portfolio (Nexavar, Kyprolis, Stivarga) isattractive and places it high on the acquisition target list.
  • 9. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comKyprolis is not restricted to R/R MM (3rd-line) and label expansionin 1st –line MM could be a blockbuster opportunity.Regeneron – Growth trajectory driven by Eylea in wet Age-relatedmacular degeneration (AMD), Central Retinal Vein Occlusion(CRVO) and Diabetic macular edema (DME,). Pipeline targetingHypercholesterolemia, Cancer and RA promises long term growth.Vertex - Bleak prospects for INICVEK as better drugs for HCV arepoised to hit the market. Kalydeco (CF potentiator) in combinationwith VX-809/VX-661 (CF corrector) for larger Cystic Fibrosisopportunity remains a binary event.Industry TablesValuation SnapshotsExpected Drug Clinical MilestonesMB sector Selected M&A ActivitiesMarketed Products PotentialPipeline Potential Thru 2017Patent Expiry – Impact On The Sector
  • 10. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comMacro Analysis• Performance of the Mature Biotech companies recommended by MP Advisorsin 2012 -report card is very impressive and we expect the positive sentimentsto prevail in 2013 and beyond• Valuation Multiples and Fundamentals- Drivers of Growth.• MP Advisors Proprietary Sum-of-The-Parts Valuation and Top Picks for 2013• Drug Approvals 2012-15• Key Milestones During 2013/14• Impact on revenue 2012-2017 from Patent Expiry and Strategies deployed tomeet the challenges.• Pipeline of Biosimilar mAbs• Joint Ventures between innovators and biosimilar players• Merger & Acquisitions Forecast- 2013-2020In-depth Company Analysis
  • 11. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com1. Acorda (ACOR)1.1. Continuing Growth in AMPYRAs Sales1.2. Ex. US Sales – Risk Factored in the Current Price1.3. Pipeline Beyond AMPYRA – AC105, diazepam1.4. Takeover target1.5. Sum of the parts valuation1.6. Background2. Alexion (ALXN)2.1. Product Pipeline – Future Potential2.2. Soliris in PNH and aHUS: Growth t-- Continue2.3. Soliris beyond PNH and aHUS2.4. Diversifying Beyond Soliris - Asfotase alfa, ALXN1102/ALXN1103,ALXN10072.5. Sum of the parts valuation
  • 12. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com3. Amgen (AMGN)3.1. Investment Drivers3.2. Pipeline Products – Promising Progress, AMG145, Romosozumab3.3. Enriched Pipeline through acquisitions or collaborations -Blinatumomab, Talimogene laherparepvec, Omecamtiv mecarbil3.4. Divest Pipeline Products Smartly3.5. Tapping Emerging markets and other Geographical Expansion3.6. Strategy for Biosimilars onslaught3.7. Sum of the parts valuation3.8. AHA 12 UPDATE: AMG 145 – HYPERLIPIDEMIA3.9. COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB – HYPERLIPIDEMIA4. Biogen Idec (BIIB)4.1. Catalysts in the Next 6-8 Months – BG-12, recombinant long-lastingFactor VIII (rFVIIFc) and IX (rFIXFc), Obinutuzumab
  • 13. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com4.2. March of Marketed Products Continues4.3. Sum of the parts valuation4.4. OBINUTUZUMAB: PHIII TRIALS4.5. RITUXIMAB BIOSIMILAR PIPELINE4.6. Other CNS drugs in the Pipeline4.7. Biosimilar Development5. Celgene (CELG)5.1. Upcoming Key Milestones – Pomalidomide, Apremilast, ABRAXANE5.2. Negative – Downside risk but not before 20195.3. Sum of the parts valuation5.4. PROTEASOME INHIBITOR - CLINICAL DATA COMPARISON: R/RMM6. Gilead (GILD)6.1. Advancements in the Anti-viral space – HIV and HCV6.2. Beyond Anti-Virals –
  • 14. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com6.3. Key Catalysts – Sofosubivir, QUAD Pill, Elvitegravir6.4. Competition from dolutegravir6.5. Pipeline beyond anti-virals – Ranexa, GS-1101 (PI3K inhibitor)6.6. Sum of the parts valuation6.7. KEY PRODUCTS IN PIPELINE: IFN-FREE COMBINATION6.8. DEVELOPMENT PIPELINE7. Grifols (GRF)7.1. Basis of OP recommendation7.2. IVIG AD Opportunity – A Wild Card but Not a Risk t-- its Core Business7.3. Capacity Matters in Plasma Business –7.4. Weakness7.5. BACKGROUND - BioScience Division, Diagnostic, Hospital7.6. NEW PROTEINS IN DEVELOPMENT7.7. FDA APPROVED PRODUCTS – FRACTIONATED PLASMA
  • 15. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comPRODUCTS8. Onyx (ONXX)8.1. Investments drivers – Kyprolis, Oprozomab, Nexavar label expansion8.2. Sum of the parts valuation8.3. KYPROLIS: ASH 12 UPDATE9. Regeneron (REGN)9.1. Investments drivers9.2. Upcoming Catalysts – Marketed Products (Eylea, ZALTRAP)9.3. Upside from Ex-Trap Late -stage Pipeline (REGN727/SAR236553,Sarilumab, REGN475)9.4. Sum of the parts valuation9.5. COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB – HYPERLIPIDEMIA9.6. Commercializing strategy9.7. Manufacturing and Global Supply Chain:
  • 16. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com9.8. VASCEPA vs. LOVAZA & EPANOVA9.9. CLINICAL DATA COMPARISON IN HYPERTRIGLYCERIDEMIA –VASCEPA vs. LOVAZA & EPANOVA10. Vertex (VRTX)10.1. INCIVEK, KALYDEC-- Label Expansion – Little t-- Bet On,10.2. Development Plans for IFN-free Combination10.3. Beyond HCV and CF – VX-509m VX-787, VX-76510.4. Sum of the parts valuation10.5. KEY PIPELINE PRODUCTS: IFN-FREE COMBINATION10.6. DEVELOPMENT PIPELINE10.7. DATA FROM IFN-FREE COMBINATIONSIndustry Tables• Valuation Snapshots• Expected Drug Clinical Milestones
  • 17. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com• MB sector Selected M&A Activities• Marketed Products Potential• Pipeline Potential Thru 2017• Patent Expiry – Impact On The Sectorn
  • 18. For more informationFor more informationReports Cornerwww.reportscorner.comFor more information please visit our websitehttps://www.reportscorner.com/reports/10017/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Mature-Biotech/
  • 19. Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: contact@reportscorner.com